BioHarvest Sciences top-line climbs 8% as CDMO segment doubles

BioHarvest Sciences (NASDAQ:BHST) reported steady growth for the first quarter of 2026, driven by a surge in its corporate contract services and the continued expansion of its flagship direct-to-consumer health products.

BioHarvest reported total revenue of $8.5 million for the quarter ended March 31, 2026, an 8% increase compared to the $7.9 million recorded in the first quarter of 2025.

The company maintained a robust gross margin of 59%, while its net loss narrowed slightly to $2.6 million, reflecting ongoing investments in scaling its manufacturing infrastructure and proprietary botanical synthesis platform.

The operational standout for the quarter was the company’s Contract Development and Manufacturing Organization (CDMO) business unit, which saw revenue grow 135% year-over-year.

The segment's momentum was anchored by several newly secured Stage 2 development contracts valued at over $2.2 million.

These programs are focused on complex botanical syntheses, including high-value rare fragrances and specialized saffron molecules, for major pharmaceutical and consumer goods clients.

On the direct-to-consumer side, BioHarvest’s VINIA® red grape powder brand reached a milestone of 90,000 active global subscribers.

The brand's newest product extension, Blood Flow Hydration, proved to be an immediate commercial catalyst, generating $920,000 in cumulative revenue since its late 2025 launch and accounting for 20% of all new customer revenue year-to-date.

Backed by a strong order pipeline in both divisions, management reiterated its full-year 2026 revenue guidance of $42 million to $48 million.